White House press secretary Jen Psaki also announced Tuesday that the federal government was increasing supply of the Moderna and Pfizer vaccines to states next week to 15.2 million doses per week, up from 14.5 million previously

Budget 2021 expectations: The pharma sector is among those sectors which would have big expectations from the Budget. The sector was in focus in 2020 as the COVID-19 pandemic ravaged lives and economies across the world

Similar to the anticipation for the COVID-19 vaccination, the healthcare industry is also looking forward to an incentive booster in the upcoming Union Budget

While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid

Centre has announced two schemes to reduce import dependence in medicine manufacturing. Will they work this time?

Covishield has been developed at the Serum Institute of India's Pune laboratory with a master seed from Oxford University/Astra Zeneca. The vaccine made in the UK is currently being tested in large efficacy trials in UK, Brazil, South Africa and USA

There is a strong chance that China may dump these products at a much lesser price once India starts production; unless countered with very quick anti-dumping measures, it may turn production of such items unsustainable for Indian industry, says BR Sikri, Chairman of Federation of Pharma Entrepreneurs

GMM Pfaudler has made strategic acquisitions, diversified its product basket and invested in new capacities with an eye on long-term growth

Alkyl Amines Chemicals, the manufacturer and supplier of specialty chemicals for pharmaceutical and agrochemical sectors, has consistently remained ahead of competition for the last few years. New products and expansion plans are set to propel its growth further

Jairam Ramesh says India depends on China for most of its active pharmaceutical ingredients, and during coronavirus-induced lockdown in May and June, API prices shot up steeply, exposing India's vulnerabilities

Currently, India imports 68 per cent APIs and more than 90 per cent antibiotics from China. the country's pharmaceutical industry is the world's third-largest in terms of volume

In a presentation made at the official launch of these schemes, the department of pharmaceuticals, Ministry of Chemicals and Fertilisers points out that the schemes when operationalised will result in import substitution and drug security for the country

Bajaj said that while India's GDP will shrink this year, it will be a 'V' shaped recovery next year unless COVID-19 hits the country very hard, which is highly unlikely

Coronavirus (COVID-19) Vaccine News Latest Updates: Dr Cyrus Poonawalla, Chairman of the Poonawalla Group, says a just a few million doses of the potential COVID-19 vaccine will not be enough and the company intends to manufacture around 1 billion doses after getting all the necessary approvals

Centre to ensure Chinese goods do not enter India via other countries like Taiwan, Singapore, Malaysia and Indonesia

The IEX data showed that both non-solar and solar RECs witnessed higher supply, with sell bids exceeding buy bids. There were buy bids for over 2.8 lakh RECs against sell bids for over 31 lakh RECs in May this year

What is more interesting is that the incentive - reimbursement of 10 to 20 percent of the net incremental sales turnover for the first four years, depending on the category you fall - will be calculated only on the revenue earned from domestic sales with a ceiling on the quantity that can be sold

The government strategy is expected to reduce dependence on China and be self reliant on the production of live saving and critical medicines throughout its production chain

Bulk drugs and intermediates that will be covered under the scheme are meant to produce vitamins, anti-TB drugs, anti-infectives, antibiotics, steroids, etc

In the middle of the current pandemic, India has emerged as a credible supplier of essential medicines